SCHEMBL2343007

SCHEMBL2343007

c1ccc(NC2CCNC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.51
MAOB P27338 3/20 0.51
MAOA P21397 1/20 0.51
HTR6 P50406 2/20 0.49
SLC6A2 P23975 2/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A3 Q01959 1/20 0.47
IDH2 P48735 1/20 0.46
CHEK2 O96017 2/20 0.45
CHEK1 O14757 1/20 0.45
JAK3 P52333 1/20 0.44
CISD1 Q9NZ45 1/20 0.42
HTR1B P28222 1/20 0.42
HTR2A P28223 1/20 0.42
AXL P30530 3/20 0.41
SOS1 Q07889 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17961734 1.00 KDM1A (0.51) KDM1AMAOBMAOAHTR6SLC6A2
Hydrochloric Acid SCHEMBL32664670 0.98 KDM1A (0.50) KDM1AMAOBMAOAHTR6SLC6A2
Hydrochloric Acid SCHEMBL14862165 0.98 KDM1A (0.50) KDM1AMAOBMAOAHTR6SLC6A2
SCHEMBL24699318 0.89 KDM1A (0.54) KDM1AMAOBHTR6IDH2CHEK2
SCHEMBL4885485 0.89 KDM1A (0.54) KDM1AMAOBHTR6IDH2CHEK2
SCHEMBL3801837 0.89 KDM1A (0.54) KDM1AMAOBHTR6IDH2CHEK2
Hydrochloric Acid SCHEMBL23360190 0.88 SLC6A2 (0.49) KDM1AMAOBMAOAHTR6SLC6A2
Hydrochloric Acid SCHEMBL23360192 0.88 SLC6A2 (0.49) KDM1AMAOBMAOAHTR6SLC6A2
SCHEMBL918020 0.88 HTR6 (0.49) KDM1AMAOBMAOAHTR6SLC6A2
Hydrochloric Acid SCHEMBL17911190 0.86 HTR6 (0.50) KDM1AMAOBMAOAHTR6SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1638933-B1 N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS PFIZER LTD (GB) 2008-06-11 EP claimed
EP-4587435-A1 MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS Cullgen (Shanghai), Inc. (CN) 2025-07-23 EP disclosed
WO-2024056077-A1 MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS CULLGEN (SHANGHAI) , INC. (CN) 2024-03-21 WO disclosed
EP-3030557-B1 A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF IDIENCE CO LTD (KR) 2023-05-31 EP disclosed
WO-2023034812-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 WO disclosed
US-RE49338-E1 Phthalazinone derivatives and manufacturing process thereof IDIENCE CO., LTD. (KR) 2022-12-20 US disclosed
CN-109153648-B Benzazepine dicarboxamide compounds having tertiary amide functional group 豪夫迈·罗氏有限公司 2022-07-22 CN disclosed
US-20200352917-A1 MEDICATED SPRAY FOR TREATMENT OF SUBSTANCE ABUSE, OVERDOSE, ADDICTION AND IMPULSE CONTROL DISORDERS GOOBERMAN LANCE L (US) 2020-11-12 US disclosed
US-10370338-B2 Benzazepine dicarboxamide compounds with tertiary amide function HOFFMANN-LA ROCHE INC. (US) 2019-08-06 US disclosed
US-20190077763-A1 BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION HOFFMANN-LA ROCHE INC. (US) 2019-03-14 US disclosed
WO-2006135644-A1 AMINOPYRIMIDINES AS KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
US-20050049286-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS INC. 2005-03-03 US disclosed
WO-2004101533-A1 1, 3, 4-BENZOTRIAZEPIN-2-ONE SALTS AND THEIR USE AS CCK RECEPTOR LIGANDS JANSSEN PHARMACEUTICA, N.V. (US) 2004-11-25 WO disclosed
WO-2004089882-A2 AROMATIC SULFONAMIDES AS PEROXYNITRITE-REARRANGEMENT CATALYSTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-10-21 WO disclosed
US-6468998-B1 ANTAGONIZE SEROTONIN 2 RECEPTORS, SUPPRESS PLATELET AGGREGATION, IMPROVE PERIPHERAL CIRCULATION AND PROMOTE LACHRYMATION MITSUBISHI PHARMA CORPORATION (JP) 2002-10-22 US disclosed
US-6410529-B1 DIETETICS; NON-INSULIN DEPENDENT DIABETES; SLEEP DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2002-06-25 US disclosed
CN-1332726-A Pyrrolidine compounds and pharmaceutical use thereof YOSHITOMI PHARMACEUTICAL (JP) 2002-01-23 CN disclosed
EP-1125922-A1 PYRROLIDINE COMPOUNDS AND MEDICINAL UTILIZATION THEREOF Welfide Corporation (JP) 2001-08-22 EP disclosed
EP-1003737-A1 PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS HFGAN72 ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2000-05-31 EP disclosed
WO-1999009024-A1 PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS HFGAN72 ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1999-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049286-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists CCR9, CCR1, CCRL2 KDM1A 4623/4885MAOB 3160/4885MAOA 3690/4885
US-10370338-B2 Benzazepine dicarboxamide compounds with tertiary amide function TLR1, TLR5, TLR4 KDM1A 395/4885MAOB 3232/4885MAOA 3120/4885
US-20190077763-A1 BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION TLR1, TLR5, TLR4 KDM1A 395/4885MAOB 3232/4885MAOA 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.